EP. 2 Available Treatment Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
EP. 7 The Evolution of AR Pathway Inhibitors and Docetaxel Utilization in mCRPC Treatment and the Impact on Cabazitaxel
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhDByAdam B. Weiner, MD,Tyler Seibert, MD, PhDAugust 21st 2026
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer careByMary Dunn, MSN, NP-C, OCN, RNAugust 20th 2026